Eugia Recalls One Lot of Vancomycin Injection Nationwide After Glass Particle Is Found
Smartor 편집팀
November 10, 2026
AI-generated explanatory illustration of pharmaceutical quality control, not a photograph of the recalled product or an actual facility.
The U.S. Food and Drug Administration on November 9 published a notice of a voluntary nationwide recall of one lot of vancomycin hydrochloride for injection from Eugia US LLC, based in East Windsor, New Jersey. The company announced the recall on November 6 after particulate matter identified as a glass particle was found inside a vial.
One lot shipped to wholesalers across the country
The recall covers Vancomycin Hydrochloride for Injection USP, 1.25 grams in a 30-milliliter single-dose vial, bearing lot number 3VM26026A and an expiration date of July 2028. The National Drug Code is 55150-471-01 on the vial and 55150-471-10 on the carton.
Eugia said the entire lot was shipped to wholesalers nationwide from September 2 through September 15, 2026. The recall extends to the hospital, healthcare facility and user level. The announcement identifies this particular lot, rather than all vancomycin products.
No related adverse events reported as of the announcement
The company said use of a product containing glass particles could cause serious health consequences, including blocked blood vessels, blood clots, pulmonary embolism, permanent organ damage or death. Its risk statement also cited local vein irritation, inflammatory reactions, worsening of existing infections and allergic reactions. Newborns, infants and patients with compromised organ function may be more susceptible, it said.
In its November 6 announcement, Eugia said it had not received any reports of adverse events related to the recall.
Vancomycin hydrochloride for injection is a glycopeptide antibacterial indicated for adults and children, including newborns, to treat septicemia, infective endocarditis, skin and skin-structure infections, bone infections and lower respiratory tract infections. Eugia said it was notifying distributors and customers through recall letters and arranging returns or replacements. The company said the recall was being conducted with the FDA’s knowledge.